4.5 Review

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

期刊

INFECTIOUS DISEASES
卷 53, 期 10, 页码 737-754

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/23744235.2021.1924397

关键词

Long-haul COVID-19; long COVID; post-COVID-19 syndrome; risk factors; pathophysiology; drug repurposing

向作者/读者索取更多资源

Long COVID or post-COVID-19 syndrome is a poorly understood condition that affects survivors with symptoms like fatigue, dyspnoea, cognitive impairments, and more. The pathophysiology, risk factors, and treatments are still lacking in literature, but potential treatments may include rehabilitation training and repurposed drugs from similar conditions. Further research is needed to substantiate risk factors and treatment options.
Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and later in scientific and medical communities. This illness is poorly understood as it affects COVID-19 survivors at all levels of disease severity, even younger adults, children, and those not hospitalized. While the precise definition of long COVID may be lacking, the most common symptoms reported in many studies are fatigue and dyspnoea that last for months after acute COVID-19. Other persistent symptoms may include cognitive and mental impairments, chest and joint pains, palpitations, myalgia, smell and taste dysfunctions, cough, headache, and gastrointestinal and cardiac issues. Presently, there is limited literature discussing the possible pathophysiology, risk factors, and treatments in long COVID, which the current review aims to address. In brief, long COVID may be driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (e.g. from viral persistence, immune dysregulation, and autoimmunity). The associated risk factors may include female sex, more than five early symptoms, early dyspnoea, prior psychiatric disorders, and specific biomarkers (e.g. D-dimer, CRP, and lymphocyte count), although more research is required to substantiate such risk factors. While preliminary evidence suggests that personalized rehabilitation training may help certain long COVID cases, therapeutic drugs repurposed from other similar conditions, such as myalgic encephalomyelitis or chronic fatigue syndrome, postural orthostatic tachycardia syndrome, and mast cell activation syndrome, also hold potential. In sum, this review hopes to provide the current understanding of what is known about long COVID.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据